145508-78-7

Usage

Uses

Used in Pharmaceutical Industry:
Icopezil is used as a cognition enhancer for the treatment of Alzheimer's disease. It helps improve cognitive function in patients by inhibiting the enzyme acetylcholinesterase, leading to an increase in the levels of the neurotransmitter acetylcholine in the brain.
Additionally, Icopezil is used as a cognition adjuvant, providing support to patients with cognitive decline associated with Alzheimer's disease. By enhancing the levels of acetylcholine, it aids in the overall cognitive performance of the patients.
Furthermore, Icopezil is utilized as an inhibitor of acetylcholinesterase, playing a crucial role in the management of Alzheimer's disease and its associated cognitive impairments.

InChI:InChI=1/C23H25N3O2/c27-23-13-18-12-19-20(25-28-22(19)14-21(18)24-23)7-6-16-8-10-26(11-9-16)15-17-4-2-1-3-5-17/h1-5,12,14,16H,6-11,13,15H2,(H,24,27)

Upstream product

• 145508-94-7 tert-butyl 4-(iodomethyl)piperidine-1-carboxylate 
• 145509-12-2 4-<2-<6,7-dihydro-6-oxo-5H-pyrrolo<3,2-f>-1,2-benzisoxazol-3-yl>ethyl>-1-piperidinecarboxylic acid, 1,1-dimethylethyl ester 
• 166756-71-4 5-acetyl-1,3-dihydro-6-hydroxy-2H-indol-2-one, 5-oxime acetate 
• 145509-11-1 5,7-dihydro-3-methyl-6H-pyrrolo<3,2-f>-1,2-benzisoxazol-6-one 
• 100-39-0 benzyl bromide 
• 179233-11-5 CP-144,885 

Relevant academic research and scientific papers

Combinations of D4 dopamine receptor antagonists with acetylcholine esterase inhibitors

The present invention relates to a method of treating dementia or cognitive deficits associated with Alzheimer's Disease or Parkinson's Disease in a mammal, including a human, by administering to the mammal a D4 dopamine receptor antagonist in combination with an acetylcholine esterase inhibitor. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a D4 dopamine receptor antagonist and an acetylcholine esterase inhibitor.

Processes and intermediates for preparing 5, 7-dihydro-3-?2-(1-benzylpiperidin-4-yl)ethyl-!6H-pyrrolo-?4, 5-F!-1, 2-benzisoxazol-6-one

This invention relates to a process for preparing the compound having the formula STR1 which comprises i) heating the compound of formula STR2 wherein R3 is R4 or benzyl and R4 is R5 C(=O), R5 C(=O) or R5 SO2 wherein R5 is (C1 -C6)alkyl or (C6 -C10)aryl(C1 -C6)alkyl; at an elevated temperature in the presence of a base with the proviso that when R3 in the resultant product is R4 said product is ii) further treated with an aqueous mineral acid at an elevated temperature followed by iii) treatment of the product of ii) with a) a benzylating agent in the presence of a base or b) benzaldohyde in the presence of a reducing agent and an acid.

METHODS OF USING PIPERIDYL-BENZISOXAZOLE AND BENISOTHIAZOLE DERIVATIVES AS CHOLINESTERASE INHIBITORS

Disclosed herein are compounds of the formula wherein R1 R2, R7, R8, X, Y, M and L are defined as below The compounds of formula I are cholinesterase inhibitors and are useful in enhancing memory in patients suffering from dementia and Alzheimer's disease

5,7-Dihydro-3-[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]-6H-pyrrolo[3,2- f]1,2-benzisoxazol-6-one: A potent and centrally-selective inhibitor of acetylcholinesterase with an improved margin of safety

A series of N-benzylpiperidines (2a-d, 10) with novel isoxazole- containing tricycles has been prepared. This series has shown potent in vitro inhibition of the enzyme acetylcholinesterase (AChE), with IC50s = 0.33- 3.6 nM. Compound 2a was the most potent inhibitor with an IC50 = 0.33 ± 0.09 nM. Derivatives 2a-d and 10 displayed weak in vitro inhibition of butyryl-cholinesterase (BuChE) with IC50s = 600-23 000 nM. The most selective compound was 2a with a BuChE/AChE ratio in excess of 4 orders of magnitude (> 10 000). Pyrrolobenzisoxazole 2a also displayed a favorable profile in vivo. In microdialysis experiments, 2a produced a 200% increase in extracellular levels of acetylcholine (ACh) at a dose of 0.4 mg/kg in freely moving, conscious rats. Peripheral side effects (salivation ED50 = 26 ± 1.5 mg/kg) and acute lethality (LD50[1 h] = 42 mg/kg) were observed at >60- fold higher doses. These data indicate that 2a is an AChE inhibitor with good central selectivity and a favorable margin of safety. Compound 2a, designated as CP-118,954, is currently in clinical development for the treatment of cognitive disorders.